Potential mechanisms of resistance to venetoclax and strategies to circumvent it

BACKGROUND: Venetoclax (ABT-199), a first-in-class orally bioavailable BCL-2-selective inhibitor, was recently approved by the FDA for use in patients with 17p-deleted chronic lymphocytic leukemia who have received prior therapy. It is also being evaluated in numerous clinical trials for treating pa...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Cancer
Autori principali: Tahir, Stephen K., Smith, Morey L., Hessler, Paul, Rapp, Lisa Roberts, Idler, Kenneth B., Park, Chang H., Leverson, Joel D., Lam, Lloyd T.
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2017
Soggetti:
Research Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5457565/
https://ncbi.nlm.nih.gov/pubmed/28578655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3383-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi